New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
09:04 EDTFLMLJudge dismisses 2007 class action case against Flamel Technologies
Flamel Technologies announced that Judge Robert Sweet of the United States District Court for the Southern District of New York issued a summary judgment on March 8 dismissing a class action suit against the company, and its former CEO. The initial class action was filed in 2007 and, during the six year period, had two different plaintiffs. The case, Billhofer v. Flamel Technologies, et al., alleged claims arising under the Securities Exchange Act of 1934 based on certain public statements by the company concerning, among other things, Coreg CR. The Company previously stated that it intended to vigorously defend itself in the action. In dismissing the case, Judge Sweet's opinion states that "as there is no genuine issue of fact and no reasonable jury could find in the lead plaintiff's favor on his claim, the motion for summary judgment is granted."
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
08:40 EDTFLMLFlamel announces positive results of LiquiTime guaifenesin clinical trial
Flamel announced the results of a First-in-Man, or FIM, clinical study in healthy volunteers using its proprietary LiquiTime drug delivery platform applied to guaifenesin, a broadly used expectorant. LiquiTime is designed to provide a controlled, extended release of oral liquids principally for pediatric and geriatric patients. The company conducted a 16-subject four-way crossover pharmacokinetic study in healthy volunteers evaluating three different BID formulations of LiquiTime guaifenesin against immediate release guaifenesin tablets dosed every 4 hours. The trial was intended to provide sufficient data for the Company to choose the best prototype to move forward into a pivotal study. While none of the prototype formulations in this relatively small pilot study exactly satisfied all of the criteria necessary for proving bioequivalence of AUC to the immediate release guaifenesin tablets under FDA requirements, the results clearly met the intention of the study. The chosen formulation will be optimized and scaled up over the coming months and Flamel plans to perform a pivotal study in 2016. There were no safety issues raised during the study. LiquiTime is protected by the company's intellectual property through late 2025 in the United States and through early 2023 in Europe.
March 20, 2015
07:21 EDTFLMLFlamel price target raised to $27 from $21 at Leerink
Subscribe for More Information
March 19, 2015
14:36 EDTFLMLFlamel price target raised to $21 from $17 at Roth Capital
Subscribe for More Information
08:10 EDTFLMLFlamel backs FY15 revenue guidance of $170M-$185M, consensus $189.58M
Subscribe for More Information
08:08 EDTFLMLFlamel reports Q4 EPS (69c), may not compare to consensus (17c)
Reports Q4 revenue $2.97M vs. $968,000 last year.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use